Chardan Capital started coverage on shares of uniQure (NASDAQ:QURE - Free Report) in a research note published on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $38.00 price objective on the biotechnology company's stock. Chardan Capital also issued estimates for uniQure's FY2025 earnings at ($3.90) EPS and FY2026 earnings at ($3.23) EPS.
Other equities analysts have also issued reports about the company. Guggenheim reissued a "buy" rating on shares of uniQure in a research note on Wednesday, December 11th. Wells Fargo & Company lowered their target price on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research report on Friday, February 28th. Stifel Nicolaus upped their price target on shares of uniQure from $12.00 to $32.00 and gave the company a "buy" rating in a research note on Monday, December 16th. Cantor Fitzgerald increased their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an "overweight" rating in a research report on Tuesday, December 10th. Finally, Raymond James upgraded shares of uniQure from an "outperform" rating to a "strong-buy" rating and boosted their target price for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $38.80.
Check Out Our Latest Analysis on uniQure
uniQure Price Performance
NASDAQ QURE traded down $0.79 on Tuesday, reaching $8.96. The company had a trading volume of 2,232,327 shares, compared to its average volume of 1,672,590. The stock has a market capitalization of $484.53 million, a PE ratio of -1.81 and a beta of 0.37. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm's 50 day moving average price is $13.25 and its 200 day moving average price is $10.91.
Insider Buying and Selling at uniQure
In other news, CEO Matthew C. Kapusta sold 6,717 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the transaction, the chief executive officer now directly owns 580,795 shares in the company, valued at approximately $6,574,599.40. This represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Christian Klemt sold 10,438 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $107,407.02. Following the completion of the transaction, the chief financial officer now directly owns 217,730 shares in the company, valued at $2,240,441.70. This represents a 4.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock valued at $961,401 in the last quarter. 4.74% of the stock is owned by insiders.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Avoro Capital Advisors LLC purchased a new position in shares of uniQure during the fourth quarter valued at $38,410,000. Franklin Resources Inc. purchased a new position in uniQure during the 3rd quarter valued at about $7,360,000. RTW Investments LP raised its holdings in shares of uniQure by 8,936.3% in the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock valued at $15,958,000 after purchasing an additional 893,625 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of uniQure by 81.3% in the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock worth $31,282,000 after purchasing an additional 794,459 shares during the period. Finally, Boxer Capital Management LLC bought a new position in shares of uniQure during the fourth quarter valued at approximately $13,245,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.
About uniQure
(
Get Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Further Reading
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
